Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II metronomic oral vinorelbine + dexamethasone in advanced castration-resistant prostate cancer
2009-015116-17Phase 2Completed
- Sponsor
- Arco Therapeutics
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and dexamethasone in castration-resistant prostate cancer (CRPC), sponsored by Arco Therapeutics. Primary endpoints: Progression-free status at 12 weeks and Change in serum PSA at 12 weeks. Started Dec 2009; status: completed.
02
Drugs
vinorelbinedexamethasone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2009-015116-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015116-17.